AKI Therapeutics A/S: Financial statements 2025
CVR: 37509736
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
AKI Therapeutics A/S (CVR 37509736) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000. The solvency ratio was 33.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -1,593,852,000
- Equity
- DKK 551,898,000
- Total Assets
- DKK 1,639,948,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | 0 | -1.6B | 551.9M | - |
| 2024 | 0 | 0 | -2M | 807K | - |
| 2023 | 0 | 0 | -1.7M | 747K | - |
| 2022 | 0 | 0 | -1.1M | 2.5M | - |
| 2021 | 0 | -12K | -1.5M | 3.6M | - |
Official annual report
How creditworthy is AKI Therapeutics A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
AKI Therapeutics A/S has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK -1,960,091.
About AKI Therapeutics A/S
AKI Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named AKI Therapeutics ApS and Renoguard ApS. The management consists of Sigbjørn Georg Nielsen Kjærgård. The board consists of Charlotte Pahl, Christian Vinding Thomsen and Lars Otto Uttenthal. The company's owners include NIELS ERIK JESPERSEN HOLDING ApS, Beier Holding ApS and FINANSMANAGEMENT ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK -1,593,852,000 compared with DKK -1,960,091 the year before. Equity in the 2025 report amounted to DKK 551,898,000.
